CCR5 and metabolic dysfunction-associated steatotic liver disease: Bone marrow transplantation, for instance, proved beneficial in murine cholestatic fibrosis but remains controversial as a treatment option for chronic liver diseases [48]; Cenicriviroc (CVC), a dual CCR2/CCR5-inhibitor impeding the infiltration of monocytes, is a promising drug candidate for NAFLD patients with fibrosis [49,50].